Osteoporosis Due to Hormone Imbalance: An Overview of the Effects of Estrogen Deficiency and Glucocorticoid Overuse on Bone Turnover.
Cheng CH, Chen LR, Chen KH. · 2022
Read Osteoporosis Due to Hormone Imbalance: An Overview of the Effects of Estrogen Deficiency and Glucocorticoid Overuse on Bone Turnover. by Cheng CH, Chen LR, Chen KH. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8836058.txt.
Introduction
Cheng, Chen, and Chen examine osteoporosis driven by hormone imbalance. One form follows estrogen loss after menopause. Bone then breaks down faster than it rebuilds. A second form follows heavy glucocorticoid use. Those drugs thin bone and raise fracture risk. The review compares the two forms side by side.
The authors explain how estrogen normally restrains bone-eating cells. They show how its loss unleashes signals that speed bone loss. They then trace how excess glucocorticoids push stem cells toward fat instead of bone. Those drugs also hasten the death of bone-building cells. Treatment sections contrast the two cases. Estrogen support leads for the first form. Limiting steroid dose leads for the second. Shared drugs, such as bisphosphonates, are also weighed.
Catalog record
| CREATOR | Cheng CH, Chen LR, Chen KH. |
|---|---|
| YEAR | 2022 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 65 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Osteoporosis Due to Hormone Imbalance: An Overview of the Effects of Estrogen Deficiency and Glucocorticoid Overuse on Bone Turnover By Chu-Han Cheng, Li-Ru Chen, Kuo-Hu Chen, Alberto Falchetti Published in: International Journal of Molecular Sciences DOI: 10.3390/ijms23031376 ABSTRACT Osteoporosis is a serious health issue among aging postmenopausal women. The majority of postmenopausal women with osteoporosis have bone loss related to estrogen deficiency. The rapid bone loss results from an increase in bone turnover with an imbalance between bone resorption and bone formation. Osteoporosis can also result from excessive glucocorticoid usage, which induces bone demineralization with significant changes of spatial heterogeneities of bone at microscale, indicating potential risk of fracture. This review is a summary of current literature about the molecular mechanisms of actions, the risk factors, and treatment of estrogen deficiency related osteoporosis (EDOP) and glucocorticoid induced osteoporosis (GIOP). Estrogen binds with estrogen receptor to promote the expression of osteoprotegerin (OPG), and to suppress the action of nuclear factor-κβ ligand (RANKL), thus inhibiting osteoclast formation and bone resorptive activity. It can also activate Wnt/β-catenin signaling to increase osteogenesis, and upregulate BMP signaling to promote mesenchymal stem cell differentiation from pre-osteoblasts to osteoblasts, rather than adipocytes. The lack of estrogen will alter the expression of estrogen target genes, increasing the secretion of IL-1, IL-6, and tumor necrosis factor (TNF). On the other hand, excessive glucocorticoids interfere the canonical BMP pathway and inhibit Wnt protein production, causing mesenchymal progenitor cells to differentiate toward adipocytes rather than osteoblasts. It can also increase RANKL/OPG ratio to promote bone resorption by enhancing the maturation and activation of osteoclast. Moreover, excess glucocorticoids are associated with osteoblast and osteocyte apoptosis, resulting in declined bone formation. The main focuses of treatment for EDOP and GIOP are somewhat different. Avoiding excessive glucocorticoid use is mandatory in patients with GIOP. In contrast, appropriate estrogen supplement is deemed the primary treatment for females with EDOP of various causes. Other pharmacological treatments include bisphosphonate, teriparatide, and RANKL inhibitors. Nevertheless, more detailed actions of EDOP and GIOP along with the safety and effectiveness of medications for treating osteoporosis warrant further investigation. 1. INTRODUCTION Osteoporosis is a serious health issue among aging postmenopausal females, who are at an increased risk of fracture. Bone mass is increased in childhood, reaching a peak level by the woman’s third or fourth decade of life. Thereafter, bone loss begins and accelerates at menopause. One study has reported that the rate of osteoporosis approximately doubled every 5 years, starting from the age of 45–49 with 3.3%, and progressively increasing to 50.3% at the age of 85 years and older [1]. The majority of postmenopausal females with osteoporosis have bone loss related to estrogen deficiency. The rapid bone loss results from an increase in bone turnover with an imbalance between bone resorption and bone formation. Glucocorticoids are the most widely used anti-inflammatory drug around the world. Despite their excellent effect in managing many acute inflammatory diseases and autoimmune disorders, the usage of glucocorticoids has been limited due to substantial adverse effects. One of the most well-known side effects is osteoporosis, which further induces bone fracture and other musculoskeletal problems. In glucocorticoid-induced osteoporosis (GIOP), glucocorticoids induce bone demineralization with significant changes of spatial heterogeneities of bone at microscale, indicating potential risk of fracture [2,3]. It is estimated that the prevalence of GIOP in the general population ranges from 0.5% to 1% with a dose-dependent effect [4]. The highest bone loss rate occurs in the first 6 months, with additional risk factors associated with primary diseases, such as chronic liver disease, chronic kidney disease, inflammatory bowel disease, autoimmune disorder, and COPD [5]. Due to changes in bone metabolism, these co-morbidities cause additional bone loss relative to glucocorticoids use alone. The impact of underlying diseases has also been recognized in children [6]. Cumulative steroid dosage, older age, female sex, and low body weight are also major risk factors of metabolic fractures [7]. GIOP has drawn public concerns to become an important health issue, and several recommendations of prevention and treatment have been published, including the American College of Rheumatology’s (ACR) guideline, which was updated in 2001 and 2010, with the latest version in 2017 [8,9,10]. Despite increasing information about GIOP, it remains clinically underdiagnosed and undertreated [11,12,13], raising concerns that enhancing education among physicians are needed [14,15,16]. Even among long-term steroid users, such as rheumatoid arthritis patients, less than 40% received recommended DEXA scanning and treatment [17,18]. In addition to discussions regarding the mechanisms, actions, and effects of glucocorticoids on bone, assessment and management of GIOP will be included as well. The understanding of the mechanisms of hormone imbalance underlying estrogen deficiency related osteoporosis (EDOP) and GIOP is essential for future prevention and treatment. This review aimed to explore the molecular mechanisms of actions, the risk factors, and treatment of patients with hormone-related osteoporosis, including EDOP and GIOP. 2. SEARCHING TERMS AND STRATEGIES FOR THE LITERATURE Figure 1 illustrates the screening, selection, and inclusion of the references we retrieved in the literature. In the current review, all of the reference articles were solicited from the databases Medline and PubMed using the search terms “osteoporosis”, “estrogen”, “glucocorticoid”, and “menopause” for the research topic. For the next stage of selection, only full-text articles were considered for inclusion in further analyses. Up to 30 June 2021, we searched potential articles in the literature from the databases Medline and PubMed. In the screening stage, duplicated articles and articles prior to 1990 were excluded. The literature published from 1 January 1990 to 30 June 2021 was searched to identify eligible articles for the review. Hereafter, two experts in the field independently inspected the contents of articles including basic data, study designs, and research outcomes, and identified potentially eligible studies for inclusion and exclusion. Research articles which had poor study designs or mismatched outcomes were excluded in this stage. To reach a consensus, disagreements between the two experts were discussed by their mutual communication. All eligible articles were included into the topic, using the searching terms and strategies (database searching, article screening, selection of eligible articles, and inclusion). Finally, a total of 108 articles were selected for review. 3. ESTROGEN DEFICIENCY-RELATED OSTEOPOROSIS (EDOP) 3.1. Molecular Mechanisms of Actions It is known that bone remodeling is accomplished by osteoblasts, osteoclasts, and osteocytes. The negative imbalance of bone remodeling, in which bone resorption exceeds bone formation, results in osteoporosis. At a cellular level, several mechanisms contribute to the bone loss related to estrogen deficiency (Figure 2). 3.1.1. Estrogen Signaling Estrogen receptors (ERs) are highly expressed in osteoblasts, osteoclasts, and osteocytes, offering protective effects in bone. Estrogen binds with ERs, which regulate the expression of estrogen target genes-encoding proteins such as IL-1, insulin-like growth factor 1 (IGF1), and TGFβ [19]. Furthermore, ERs can also suppress the action of nuclear factor-κβ ligand (RANKL), thus inhibiting osteoclast formation and bone resorptive activity [20]. The lack of estrogen will alter the expression of estrogen target genes, increasing the secretion of IL-1, IL-6, and tumor necrosis factor (TNF). Studies have also shown that estrogen deficiency directly affects cell differentiation and apoptosis [21]. The net effects of estrogen deficiency are increased bone turnover and enhanced bone resorption, which result in osteoporosis. 3.1.2. In Osteoblasts Several pathways are